Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Contact

Board

Company Overview

Team

Corporate Governance

Corporate Directory

Values

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Top 20 Shareholders

Share Price

Investor Centre

Clinical Trial

Webinars

Home

Montserrat

Amplia Therapeutics Limited

upload.jpg

Amplia Therapeutics has today released its Appendix 4C Cash Flow Report for the quarter ending 31 March 2025.

ACCENT Trial Progress: The Phase 2a ACCENT trial completed recruitment two months ahead of schedule.

Promising Initial Results: Interim data from the ACCENT trial shows 13 patients achieved confirmed partial responses, suggesting the narmafotinib combination may be more effective than chemotherapy alone.

FOLFIRINOX Trial Advancement: Significant progress has been made in initiating a second trial in the US and Australia, combining narmafotinib with FOLFIRINOX.

FDA Feedback: The FDA provided positive feedback on modifications to the FOLFIRINOX trial protocol.

Appendix 4C Cash Flow Report | Quarter ending 31 March 2025

Appendix 4C Cash Flow Report | Quarter ending 31 March 2025

Appendix 4C Cash Flow Report | Quarter ending 31 March 2025